Neoantigens tested were chosen based on a measure of neoantigen “fitness” that accounts for: the neoantigen binding affinity to the patient’s MHC; its potential for being recognized by T cells, quantified by sequence similarity to infectious disease-related epitopes (“cross-reactive”), see [9, 16]. This evidence concerns the gene HLA-C and infectious disease.